| Variables | NLR | P value | CAR | P value | ||
| High | Low | High | Low | |||
| Sex |
|
|
|
|
|
|
| Female | 10 (35.7%) | 18 (64.3%) | 0.958 | 16 (57.1%) | 12 (42.9%) | 0.973 |
| Male | 21 (63.3%) | 12 (36.4%) | 19 (57.6%) | 14 (42.4%) | ||
| Age |
|
|
|
|
|
|
| ≤18 months | 1 (4.0%) | 24 (96.0%) | 0.000 | 6 (24.0%) | 19 (76.0%) | 0.000 |
| >18 months | 21 (58.3%) | 15 (41.7%) | 29 (80.6%) | 7 (19.4%) | ||
| ALB |
|
|
|
|
|
|
| ≥35 g/L | 20 (43.5%) | 26 (56.5%) | 0.035 | 29 (63.0%) | 17 (37.0%) | 0.117 |
| <35 g/L | 2 (13.3%) | 13 (86.7%) | 6 (40.0%) | 9 (60.0%) | ||
| LDH |
|
|
|
|
|
|
| ≤400 U/L | 7 (17.9%) | 32 (82.1%) | 0.000 | 16 (41.0%) | 23 (59.0%) | 0.001 |
| >400 U/L | 15 (68.2%) | 7 (31.8%) | 19 (86.4%) | 3 (13.6%) | ||
| WBC |
|
|
|
|
|
|
| ≤10 × 109/L | 6 (15.8%) | 32 (84.2%) | 0.000 | 18 (47.4%) | 20 (52.6%) | 0.042 |
| >10 × 109/L | 16 (69.6%) | 7 (30.4%) | 17 (73.9%) | 6 (26.1%) | ||
| Tumor size |
|
|
|
|
|
|
| ≤5 cm | 1 (4.3%) | 22 (95.7%) | 0.000 | 5 (21.7%) | 18 (78.3%) | 0.000 |
| >5 cm | 21 (55.3%) | 17 (44.7%) | 30 (78.9%) | 8 (21.1%) | ||
| Site |
|
|
|
|
|
|
| Non-Adrenal | 6 (33.3%) | 12 (66.7%) | 0.774 | 12 (66.7%) | 6 (33.3%) | 0.343 |
| Adrenal | 16 (37.2%) | 27 (62.8%) | 23 (53.5%) | 20 (46.5%) | ||
| Chemotherapy |
|
|
|
|
|
|
| Yes | 15 (34.1%) | 29 (65.9%) | 0.605 | 24 (54.5%) | 20 (45.5%) | 0.472 |
| No | 7 (41.2%) | 10 (58.8%) | 11 (64.7%) | 6 (35.3%) | ||
| INSS Stage |
|
|
|
|
|
|
| I-II | 3 (11.5%) | 23 (88.5%) | 0.001 | 9 (34.6%) | 17 (65.4%) | 0.002 |
| III-IV | 19 (54.3%) | 16 (45.7%) | 26 (74.3%) | 9 (25.7%) | ||